LEttERS to tHE EDItoR
To the Editor, X-linked lymphoproliferative disease (XLP) is a rare disorder characterized by an extreme vulnerability to EpsteinBarr virus (EBV) infection, frequently resulting in hemophagocytic lymphohistiocytosis (HLH) [1] . XLP-1, its more common subtype, is caused by defects in the SH2D1A gene that encodes the signaling lymphocyte activation molecule-associated protein (SAP), which regulates the activation of T lymphocytes [2] , whereas XLP-2 is caused by mutations in the XIAP gene, also known as BIRC4 [3] .
We present here an XLP-1 patient with a family history of the death of multiple male children, who presented with EBVtriggered fatal HLH. To our knowledge, this is the first report of an SH2D1A mutation from Turkey.
Case:
The 19-month-old male patient, admitted with the complaints of fever and abdominal distention, had pale appearance, fever (body temperature: 39.5 °C), dyspnea, tachycardia, abdominal distention, and hepatosplenomegaly. Laboratory findings are summarized in Table 1 .
In the family history, the death of a 2-year-old male sibling with the clinical diagnosis of HLH and of five young male children of unknown etiology among maternal relatives was noted (Figure 1 ).
The patient received intravenous immunoglobulin. However, in the follow-up, fever recurred and his general condition worsened. Bone marrow aspiration revealed hemophagocytosis. Therefore, the patient fulfilled the HLH diagnostic criteria. Plasma exchange was performed. Blood products, antimicrobials, and supportive therapeutic agents were used as indicated.
The results of EBV serologic testing and polymerase chain reaction were both reported as positive. On the 6 th hospitalization day, the HLH-2004 protocol treatment was initiated, and rituximab therapy was planned. Continuous veno-venous hemodialysis was performed. However, the vital signs of the patient deteriorated further and active gastrointestinal bleeding was observed. The patient died on the 10 th day of hospitalization.
In the cytotoxic lymphocyte activity analysis, low SAP expression in addition to signs of severe immunoactivation was detected (Figure 1 ). In the genetic analysis performed in the Clinical Genetics Unit of Karolinska University Hospital, Stockholm, Sweden, the c.163C>T (p.Arg55Ter) mutation in the SH2D1A gene, described previously as pathologic [4] , was identified ( Figure 1 ). Genetic counseling was provided to the family. This letter was written after receiving informed consent from the parents.
We report here an XLP-1 case in which the patient presented with EBV-associated HLH. Although no genetic analysis was performed among the male relatives of the patient lost previously in childhood, XLP-1 seems to be the underlying cause in those children as well.
In XLP cases, the most common clinical manifestation is fulminant infectious mononucleosis (frequency: 58%, survival: 4% 
